cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytosorbents Corp
11 own
12 watching
Current Price
$0.92
$0.01
(1.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
81.64M
52-Week High
52-Week High
1.59000
52-Week Low
52-Week Low
0.69999999
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization81.64M
icon52-Week High1.59000
icon52-Week Low0.69999999
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio--
What does the Cytosorbents Corp do?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Read More
How much money does Cytosorbents Corp make?
News & Events about Cytosorbents Corp.
Globe Newswire
1 year ago
CytoSorbents Hosts Research Symposium at ISICEM CytoSorbents Highlights New Clinical Data from Current Studies at the 2023 International Symposium on Intensive Care & Emergency Medicine PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the ...
PR Newswire
1 year ago
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference PR Newswire PRINCETON, N.J., Feb. 27, 2023 PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the treatment...
PR Newswire
1 year ago
CytoSorbents to Report Fiscal 2022 Operating and Financial Results CytoSorbents to Report Fiscal 2022 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J., Feb. 24, 2023 MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the...
Ticker Report
1 year ago
StockNews.com lowered shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a hold rating to a sell rating in a research note released on Thursday. Separately, HC Wainwright decreased their target price on Cytosorbents from $9.00 to $5.50 and set a buy rating for the company in a research ...
Ticker Report
1 year ago
StockNews.com upgraded shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a sell rating to a hold rating in a research report report published on Thursday morning. Separately, HC Wainwright cut their price objective on Cytosorbents from $9.00 to $5.50 and set a buy rating on the stock in a...
Frequently Asked Questions
Frequently Asked Questions
What is Cytosorbents Corp share price today?
plus_minus_icon
Can Indians buy Cytosorbents Corp shares?
plus_minus_icon
How can I buy Cytosorbents Corp shares from India?
plus_minus_icon
Can Fractional shares of Cytosorbents Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cytosorbents Corp stocks?
plus_minus_icon
What is today’s traded volume of Cytosorbents Corp?
plus_minus_icon
What is today’s market capitalisation of Cytosorbents Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cytosorbents Corp?
plus_minus_icon
What percentage is Cytosorbents Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cytosorbents Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$0.92
$0.01
(1.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Apyx Medical Corp
Apyx Medical Corp
$1.57
$-0.00 (-0.32 %)
INFUSYSTEM HOLDINGS INC
INFUSYSTEM HOLDINGS INC
$8.08
$-0.37 (-4.38 %)
Lantheus Holdings
Lantheus Holdings
$88.80
$-0.66 (-0.74 %)
IRADIMED CORP
IRADIMED CORP
$54.94
$-0.06 (-0.11 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Apyx Medical Corp
Apyx Medical Corp
$1.57
$-0.00 (-0.32 %)
INFUSYSTEM HOLDINGS INC
INFUSYSTEM HOLDINGS INC
$8.08
$-0.37 (-4.38 %)
Lantheus Holdings
Lantheus Holdings
$88.80
$-0.66 (-0.74 %)
IRADIMED CORP
IRADIMED CORP
$54.94
$-0.06 (-0.11 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00